Effect of non-nucleoside reverse transcriptase inhibitors on cytokine, chemokine, and immunoglobulin profiles in serum and genital secretions of HIV-infected women

Journal of Interferon and Cytokine Research

Volumn 30, Issue 5, 2010, Pages 299-310

  Sachdeva, Ravinder Kaur ^a   Wanchu, Ajay ^a   Bagga, Rashmi ^a   Malla, Nancy ^a   Sharma, Meera ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; BETA CHEMOKINE; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RANTES; STROMAL CELL DERIVED FACTOR 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; P24 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS TYPE 1; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VAGINAL LAVAGE; VIRUS LOAD; BODILY SECRETIONS; DOWN REGULATION; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM; PATHOGENICITY;

ADULT; BODILY SECRETIONS; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; VAGINAL DOUCHING; VIRAL LOAD;

EID: 77952560259     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2009.0056     Document Type: Article

References (33)

1. Belec L, Dupre T, Prazuck T, Tevi-Benissan C, Kanga JM, Pathey O, Lu XS, Pillot J. 1995a. Cervicovaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection. J Infect Dis 172(3):691-697.
2. Belec L, Georges AJ, Steenman G, Martin PM. 1989. Antibodies to human immunodeficiency virus in vaginal secretions of heterosexual women. J Infect Dis 160(3):385-391.
3. Belec L, Ghys PD, Hocini H, Nkengasong JN, Tranchot-Diallo J, Diallo MO, Ettiegne-Traore V, Maurice C, Becquart P, Matta M, Si-Mohamed A, Chomont N, Coulibaly IM, Wiktor SZ, Kazatchkine MD. 2001. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J Infect Dis 184(11):1412-1422.
4. Belec L, Meillet D, Levy M, Georges A, Tevi-Benissan C, Pillot J. 1995b. Dilution assessment of cervicovaginal secretions obtained by vaginal washing for immunological assays. Clin Diagn Lab Immunol 2(1):57-61.
5. Breen EC, McDonald M, Fan J, Boscardin J, Fahey JL. 2000. Cytokine gene expression occurs more rapidly in stimulated peripheral blood mononuclear cells from human immunodeficiency virusinfected persons. Clin Diagn Lab Immunol 7(5):769-773.
6. Cecilia D, Kulkarni SS, Tripathy SP, Gangakhedkar RR, Paranjape RS, Gadkari DA. 2000. Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India. Virology 271(2):253-258.
7. Coombs RW, Wright DJ, Reichelderfer PS, Burns DN, Cohn J, Cu-Uvin S, Baron PA, Cohen MH, Landay AL, Lewis S, Kovacs A; Women's Health Study 001 Team. 2001. Variation of human immunodeficiency virus type 1 viral RNA levels in the female genital tract: implications for applying measurements to individual women. J Infect Dis 184(9):1187-1191.
8. Croft M, Carter L, Swain SL, Dutton RW. 1994. Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 180(5):1715-1728.
9. Crowley-Nowick PA, Ellenberg JH, Vermund SH, Douglas SD, Holland CA, Moscicki AB. 2000. Cytokine profile in genital tract secretions from female adolescents: impact of human immunodeficiency virus, human papillomavirus, and other sexually transmitted pathogens. J Infect Dis 181(3):939-945.
10. di Marzio P, Mariani R, Lui R, Thomas EK, Landau NR. 2000. Soluble CD40 ligand induces beta-chemokine production by macrophages and resistance to HIV-1 entry. Cytokine 12(10):1489-1495.
11. Hogan CM, Hammer SM. 2001. Host determinants in HIV infection and disease. Part 1: cellular and humoral immune responses. Ann Intern Med 134(9 Pt 1):761-776.
12. Iqbal SM, Ball TB, Kimani J, Kiama P, Thottingal P, Embree JE, Fowke KR, Plummer FA. 2005. Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers. J Infect Dis 192(5):728-738.
13. Iversen AK, Fugger L, Eugen-Olsen J, Balslev U, Jensen T, Wahl S, Gerstoft J, Mullins JI, Skinhoj P. 1998. Cervical human immunodeficiency virus type 1 shedding is associated with genital betachemokine secretion. J Infect Dis 178(5):1334-1342.
14. Jennes W, Vereecken C, Fransen K, de Roo A, Kestens L. 2004. Disturbed secretory capacity for macrophage infl ammatory protein (MIP)-1 alpha and MIP-1 beta in progressive HIV infection. AIDS Res Hum Retroviruses 20(10):1087-1091.
15. Kaul R, Trabattoni D, Bwayo JJ, Arienti D, Zagliani A, Mwangi FM, Kariukic, Ngugi EN, MacDonald KS, Ball TB, Clerici M, Plummer FA. 1999. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 13(1):23-29.
16. Lehner T, Anton PA. 2002. Mucosal immunity and vaccination against HIV. AIDS 16(Suppl 4):S125-S132.
17. Lu XS, Belec L, Pillot J. 1993. Anti-gp160 IgG and IgA antibodies associated with a large increase in total IgG in cervicovaginal secretions from human immunodeficiency virus type 1-infected women. J Infect Dis 167(5):1189-1192.
18. Lusso P. 2006. HIV and the chemokine system: 10 years later. EMBO J 25(3):447-456.
19. Mazzoli S, Trabattoni D, Lo Caputo S, Piconi S, Ble C, Meacci F, Ruzzante S, Salvi A, Semplici F, Longhi R, Fusi ML, Tofani N, Biasin M, Villa ML, Mazzotta F, Clerici M. 1997. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 3(11):1250-1257.
20. Olaitan A, Johnson MA, MacLean A, Poulter LW. 1996. The distribution of immunocompetent cells in the genital tract of HIVpositive women. AIDS 10(7):759-764.
21. Olaitan A, Johnson MA, Reid WM, Poulter LW. 1998. Changes to the cytokine microenvironment in the genital tract mucosa of HIV+ women. Clin Exp Immunol 112(1):100-104.
22. Orsilles MA, Pieri E, Cooke P, Caula C. 2006. IL-2 and IL-10 serum levels in HIV-1-infected patients with or without active antiretroviral therapy. APMIS 114(1):55-60.
23. Prakash M, Patterson S, Kapembwa MS. 2001. Macrophages are increased in cervical epithelium of women with cervicitis. Sex Transm Infect 77(5):366-369.
24. Poli G, Fauci AS. 1993. Cytokine modulation of HIV expression. Semin Immunol 5(3):165-173.
25. Schwartz SA, Nair MP. 1999. Current concepts in human immunodeficiency virus infection and AIDS. Clin Diagn Lab Immunol 6(3):295-305.
26. Sha BE, D'Amico RD, Landay AL, Spear GT, Massad LS, Rydman RJ, Warner NA, Padnick J, Ackatz L, Charles LA, Benson CA. 1997. Evaluation of immunologic markers in cervicovaginal fl uid of HIV-infected and uninfected women: implications for the immunologic response to HIV in the female genital tract. J Acquir Immune Defic Syndr Hum Retrovirol 16(3):161-168.
27. Si-Mohamed A, Andreoletti L, Colombet I, Carreno MP, Lopez G, Chatelier G, Kazatchkine MD, Belec L. 2001. Quantitation of human immunodeficiency virus type 1 (HIV-1) RNA in cell-free cervicovaginal secretions: comparison of reverse transcription-PCR amplification (AMPLICOR HIV-A MONITOR 1.5) with enhanced-sensitivity branched-DNA assay (Quantiplex 3.0). J Clin Microbiol 39(6):2055-2059.
28. Spear GT, Sha BE, Saarloos MN, Benson CA, Rydman R, Massad LS, Gilmore R, Landay AL. 1998. Chemokines are present in the genital tract of HIV-seropositive and HIV-seronegative women: correlation with other immune mediators. J Acquir Immune Defic Syndr Hum Retrovirol 18(5):454-459.
29. Sturm-Ramirez K, Gaye-Diallo A, Eisen G, Mboup S, Kanki PJ. 2000. High levels of tumor necrosis factor-alpha and interleukin-1beta in bacterial vaginosis may increase susceptibility to human immunodeficiency virus. J Infect Dis 182(2):467-473.
30. Voltersvik P, Albrektsen G, Ulvestad E, Dyrhol-Riise AM, Sorensen B, Asjo B. 2003. Changes in immunoglobulin isotypes and immunoglobulin G (IgG) subclasses during highly active antiretroviral therapy: anti-p24 IgG1 closely parallels the biphasic decline in plasma viremia. J Acquir Immune Defic Syndr 34(4):358-367.
31. Williams SB, Flanigan TP, Cu-Uvin S, Mayer K, Williams P, Ettore CA, Artenstein AW, Duerr A, VanCott TC. 2002. Human immunodeficiency virus (HIV)-specific antibody in cervicovaginal lavage specimens obtained from women infected with HIV type 1. Clin Infect Dis 35(5):611-617.
32. World Health Organization. 2002. Scaling up antiretroviral therapy in resource-limited settings. www.who.int/docstore/hiv/scaling/ summ.html
33. Zara F, Nappi RE, Brerra R, Migliavacca R, Maserati R, Spinillo A. 2004. Markers of local immunity in cervico-vaginal secretions of HIV infected women: implications for HIV shedding. Sex Transm Infect 80(2):108-112.